A1 beta-casein in conventional milk releases beta-casomorphin-7, which triggers gut inflammation, slower transit and worse symptoms (shown in a 2016 randomised trial).

Original statement

يُضاف لذلك بروتين بيتا-كازين A1 في الحليب التقليدي، الذي أثبتت تجربة Nutrition Journal عام 2016 أنه يُنتج ببتيد بيتا-كازومورفين-7 المسبّب لالتهاب الأمعاء وبطء الحركة الهضمية.

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

A1 beta-casein in conventional milk releases beta-casomorphin-7, which triggers gut inflammation, slower transit and worse symptoms (shown in a 2016 randomised trial).

Origin

Source status

Archive editors

Attribution

Archive editors (eltayebat.com, rule 'dairy')

Origin

https://eltayebat.com/rule/dairy/

Attribution uncertainty

Editorial narrative and study selection by the archive operators, not shown to be Elawady's own words; the archive homepage says the forbidden section is documented 'independently of Dr. Diaa's words'.

Claimed mechanism

Opioid peptide beta-casomorphin-7 from A1 beta-casein digestion.

Claimed health effect

Gut inflammation, delayed transit, digestive discomfort, slower cognition.

Population concerned

People with self-reported milk intolerance (trial population); archive generalises.

Geographic restriction by Elawady

none found

Scientific assessment

Unclear / insufficient evidence – The data do not allow an assessment either way.

Certainty of evidence: low – Further research is likely to change the assessment considerably.

1. What was claimed?

A1 beta-casein causes gut inflammation and slow transit via BCM-7.

2. What is demonstrably correct?

A-DRY-10 found more digestive symptoms (bloating, flatulence), longer colonic (+6.6 h) and whole-gut (+6.3 h) transit and higher IL-4, IgE and IgG with A1+A2 milk vs A2-only milk in Chinese adults with self-reported intolerance. An independent systematic review (I-DRY-04, GRADE) concluded 'moderate certainty for adverse digestive health effects of A1 beta-casein compared with A2'. In lactose-intolerant women, A2 milk caused fewer symptoms in a small trial (I-DRY-116).

3. What is wrong or exaggerated?

A-DRY-10 was designed and funded by The a2 Milk Company; 2-week periods; 45 participants; no adjustment for multiple testing; beta-casomorphin-7 concentrations are claimed in the abstract but not reported in the results, so 'shown in a 2016 randomised trial' is not verifiable. Newer blinded trials did not confirm the effects: no differences in symptoms, transit (measured by ingestible sensor) or IgG, IgE, IL-4 (I-DRY-114, n=50), and no difference between A2 and A1 milk in lactose-tolerant people, with no rise in calprotectin or hs-CRP during milk periods (I-DRY-115). Lactose appears to explain much of the discomfort. The comparison is A1 vs A2 milk, not milk vs no milk, and cheese contains the same caseins.

4. What remains unclear?

Whether BCM-7 effects in fermented/aged cheese differ; effects beyond symptoms.

5. Which studies support it?

A-DRY-10 (symptoms and transit; BCM-7 data not reported; high risk of bias); I-DRY-04 (digestive symptoms, moderate certainty); I-DRY-05 (industry-linked review); I-DRY-116 (benefit only in lactose-intolerant women).

6. Which studies contradict it?

I-DRY-114 (blinded RCT: no differences in symptoms, transit or immune markers); I-DRY-115 (A2 v A1 no difference in lactose-tolerant people; no rise in calprotectin/hs-CRP); I-DRY-04 (most RCTs on intermediate markers found no difference).

7. What applies to Germany and Europe?

EFSA reviewed beta-casomorphins in 2009 (report could not be accessed for this review; not used).

8. What is known about Egypt?

Egyptian cow and buffalo milk A1/A2 composition not examined here.

9. What practical conclusion is appropriate?

Some people, especially those with lactose malabsorption, may feel better with A2 or lactose-free milk; this is an individual tolerance question and does not justify banning fresh milk while allowing casein-rich cheese.

Assessment details

Rationale for certainty of evidence

Earlier, mostly industry-funded trials (A-DRY-10, summarised in I-DRY-04/I-DRY-05) reported more digestive symptoms with A1 than A2 milk, but newer blinded crossover trials found no differences in symptoms, gut transit or inflammation markers (I-DRY-114, sponsored by an A2 milk company; I-DRY-115), and one trial found an A2 benefit only in lactose-intolerant women (I-DRY-116). The key 2016 trial does not report its beta-casomorphin-7 results and is at high risk of bias. The evidence is conflicting and of low certainty.

Source quality

Archive editorial; 'proved' (أثبتت) overstates a single 45-person, industry-funded crossover trial.

Regional transferability

Trial in Han Chinese adults with self-reported lactose intolerance; transfer to other populations uncertain.

Individual exceptions

People who tolerate milk poorly may test A2 milk; this is an individual intolerance issue.

Regional scope of the claim

general (biological/medical)

Last reviewed

26 October 2026 provisional

Scientific evidence in detail

Overinterpreted – A real finding exists, but the claim draws more from it than the data allow (e.g. association taken as cause, animal data applied to humans, small effect presented as large).

Research question: Does A1 beta-casein in conventional milk cause gut inflammation, slower transit and more symptoms compared with A2-only milk?

Study results as reported by the authors. Our assessment follows below.

Open questions

Large independent trials stratified by lactase status; BCM-7 measurements.

How deeply was this checked?

6 linked studies: 1 checked in full text (1 of them with a structured risk-of-bias assessment), 5 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

In plain language

Cow's milk contains two forms of a protein called beta-casein, A1 and A2. A small trial in China, paid for by an A2 milk company, found more stomach symptoms with ordinary milk than with A2-only milk. Newer blinded trials in other countries found no difference in symptoms, gut speed or inflammation markers, and milk sugar (lactose) seemed to explain most complaints. So it is unclear whether A1 protein matters at all, and there is no reliable evidence that it inflames the gut. Cheese contains the same proteins.

Studies on this claim

Regional context

Germany / EU

EFSA reviewed beta-casomorphins in 2009 (report could not be accessed for this review; not used).

Egypt

Egyptian cow and buffalo milk A1/A2 composition not examined here.

• Antimicrobial use in food animals and antibiotic growth promoters
• Hormones in poultry, meat, milk and farmed fish
• Dioxins, PCBs and PFAS in eggs and other animal foods
• Aflatoxin M1 in milk and dairy products
• Import controls and the meaning of RASFF notifications for Egyptian products

What applies in my country?

General scientific assessment

Unclear / insufficient evidence It is unclear whether A1 beta-casein causes more digestive discomfort than A2, and there is no reliable evidence that it causes gut inflammation; the finding would in any case concern milk types, not milk versus cheese.

The following areas of food safety are relevant to this statement:

• Veterinary medicines and antibiotics
• Hormonal growth promoters
• Contaminants (heavy metals, PFAS, PCBs, dioxins, nitrate)
• Mycotoxins (mould toxins)
• Controls, imports, recalls, labelling

Dairy

Limits: legal rules describe what is allowed, not what every single food contains. Measurement data come from samples and are meaningful only together with their method details.

Country of residence or purchase Compare with another country

References

1. Effects of milk containing only A2 beta casein versus milk containing both A1 and A2 beta casein proteins on gastrointestinal physiology, symptoms of discomfort, and cognitive behavior of people with self-reported intolerance to traditional cows' milk.. Jianqin S et al.. Nutr J 2016 · PMID 27039383 · DOI 10.1186/s12937-016-0147-z
2. Systematic Review of the Gastrointestinal Effects of A1 Compared with A2 β-Casein.. Brooke-Taylor S et al.. Adv Nutr 2017 · PMID 28916574 · DOI 10.3945/an.116.013953
3. Comparative effects of conventional cow's milk versus milk free of A1-type beta-casein on gastrointestinal physiology and symptoms of digestive discomfort in participants intolerant to conventional cow's milk: a pilot randomised controlled trial.. Greenway FL et al.. Nutr J 2026 · PMID 41634798 · DOI 10.1186/s12937-026-01288-9
4. Tolerance of protein-hydrolyzed lactose-free A1 milk and A2 milk in lactose-tolerant and lactose-intolerant volunteers: A randomized crossover trial with 2 parallel groups.. Mannila E et al.. J Dairy Sci 2025 · PMID 40614809 · DOI 10.3168/jds.2025-26712
5. Milk A1 β-casein and health-related outcomes in humans: a systematic review.. Küllenberg de Gaudry D et al.. Nutr Rev 2019 · PMID 30722004 · DOI 10.1093/nutrit/nuy063
6. Comparison of the impact of bovine milk beta-casein variants on digestive comfort in females self-reporting dairy intolerance: a randomized controlled trial.. Milan AM et al.. Am J Clin Nutr 2020 · PMID 31773165 · DOI 10.1093/ajcn/nqz279